新聞/Reuters/Glenmark Pharma Says Unit IGI Submits IND Application To U.S. FDA For ISB 2301 Targeting Solid TumorsGlenmark Pharma Says Unit IGI Submits IND Application To U.S. FDA For ISB 2301 Targeting Solid Tumors閱讀全文無限制訪問Reuters以及TradingView所有其他新聞來源的文章。繼續閱讀